Uterine Corpus Carcinosarcoma — Trials

Uterine Corpus Carcinosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 4
Ph III recruiting: 3
Growth YoY: —
Industry share: 0%
Top sponsor: ARCAGY/ GINECO GROUP
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03651206	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN)	recruiting	Phase 2 / Phase 3	138	ARCAGY/ GINECO GROUPOTHER	3	Sep 9, 2026	clinicaltrials
NCT05156268	A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma	completed	Phase 2	26	Memorial Sloan Kettering Cancer CenterOTHER	1	Apr 27, 2026	clinicaltrials